CN111803593A - Antiviral traditional Chinese medicine composition, preparation method and application thereof - Google Patents
Antiviral traditional Chinese medicine composition, preparation method and application thereof Download PDFInfo
- Publication number
- CN111803593A CN111803593A CN202010482309.4A CN202010482309A CN111803593A CN 111803593 A CN111803593 A CN 111803593A CN 202010482309 A CN202010482309 A CN 202010482309A CN 111803593 A CN111803593 A CN 111803593A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- virus
- specifically
- mint
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 239000003814 drug Substances 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 230000000840 anti-viral effect Effects 0.000 title abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 42
- 235000001405 Artemisia annua Nutrition 0.000 claims abstract description 28
- 240000000011 Artemisia annua Species 0.000 claims abstract description 28
- 235000006679 Mentha X verticillata Nutrition 0.000 claims abstract description 27
- 235000002899 Mentha suaveolens Nutrition 0.000 claims abstract description 27
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims abstract description 27
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 21
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 21
- 235000008434 ginseng Nutrition 0.000 claims abstract description 21
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 20
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 20
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 20
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 19
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 claims abstract description 19
- 244000035851 Chrysanthemum leucanthemum Species 0.000 claims abstract description 19
- 240000003915 Lophatherum gracile Species 0.000 claims abstract description 19
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 18
- 235000011477 liquorice Nutrition 0.000 claims abstract description 18
- 235000013305 food Nutrition 0.000 claims abstract description 11
- 241000711573 Coronaviridae Species 0.000 claims abstract description 10
- 241001678559 COVID-19 virus Species 0.000 claims abstract description 7
- 238000011282 treatment Methods 0.000 claims abstract description 6
- 230000002265 prevention Effects 0.000 claims abstract description 4
- 239000000463 material Substances 0.000 claims description 38
- 239000000843 powder Substances 0.000 claims description 30
- 239000007788 liquid Substances 0.000 claims description 20
- 235000009508 confectionery Nutrition 0.000 claims description 13
- 235000013376 functional food Nutrition 0.000 claims description 12
- 244000042430 Rhodiola rosea Species 0.000 claims description 10
- 235000003713 Rhodiola rosea Nutrition 0.000 claims description 10
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 10
- 241000700605 Viruses Species 0.000 claims description 10
- 230000009385 viral infection Effects 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 7
- 241000208340 Araliaceae Species 0.000 claims description 6
- 235000013361 beverage Nutrition 0.000 claims description 5
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 241000711950 Filoviridae Species 0.000 claims description 3
- 241000711467 Human coronavirus 229E Species 0.000 claims description 3
- 241001109669 Human coronavirus HKU1 Species 0.000 claims description 3
- 241000482741 Human coronavirus NL63 Species 0.000 claims description 3
- 241001428935 Human coronavirus OC43 Species 0.000 claims description 3
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 235000003599 food sweetener Nutrition 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000003765 sweetening agent Substances 0.000 claims description 3
- 241000701242 Adenoviridae Species 0.000 claims description 2
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 2
- 241001115402 Ebolavirus Species 0.000 claims description 2
- 241000700739 Hepadnaviridae Species 0.000 claims description 2
- 241000700586 Herpesviridae Species 0.000 claims description 2
- 241000712431 Influenza A virus Species 0.000 claims description 2
- 241000713196 Influenza B virus Species 0.000 claims description 2
- 241000712079 Measles morbillivirus Species 0.000 claims description 2
- 241000711386 Mumps virus Species 0.000 claims description 2
- 241000711408 Murine respirovirus Species 0.000 claims description 2
- 241000712464 Orthomyxoviridae Species 0.000 claims description 2
- 241000711504 Paramyxoviridae Species 0.000 claims description 2
- 241000709664 Picornaviridae Species 0.000 claims description 2
- 241000700625 Poxviridae Species 0.000 claims description 2
- 241000702247 Reoviridae Species 0.000 claims description 2
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 2
- 241000712907 Retroviridae Species 0.000 claims description 2
- 241000711931 Rhabdoviridae Species 0.000 claims description 2
- 108700010877 adenoviridae proteins Proteins 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 241000304195 Salvia miltiorrhiza Species 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 208000025721 COVID-19 Diseases 0.000 abstract description 6
- 241000315672 SARS coronavirus Species 0.000 abstract description 5
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 abstract description 4
- 206010057190 Respiratory tract infections Diseases 0.000 abstract description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 230000002155 anti-virotic effect Effects 0.000 abstract 1
- 238000000605 extraction Methods 0.000 description 22
- 238000002386 leaching Methods 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 240000004371 Panax ginseng Species 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 238000001035 drying Methods 0.000 description 12
- 238000001914 filtration Methods 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- 238000003745 diagnosis Methods 0.000 description 10
- -1 etc.) Substances 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 210000002216 heart Anatomy 0.000 description 8
- 244000132619 red sage Species 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 206010011224 Cough Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 238000003672 processing method Methods 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000002791 soaking Methods 0.000 description 6
- 238000001694 spray drying Methods 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 241000726041 Human respirovirus 1 Species 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 5
- 229940107187 fructooligosaccharide Drugs 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 208000013220 shortness of breath Diseases 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 206010008479 Chest Pain Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 208000006083 Hypokinesia Diseases 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 description 3
- 206010038743 Restlessness Diseases 0.000 description 3
- 240000002547 Rosa roxburghii Species 0.000 description 3
- 235000000640 Rosa roxburghii Nutrition 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- 241000208838 Asteraceae Species 0.000 description 2
- 208000001528 Coronaviridae Infections Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 241000207923 Lamiaceae Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 240000005809 Prunus persica Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 241000700647 Variola virus Species 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 229920001531 copovidone Polymers 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 235000019633 pungent taste Nutrition 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000011446 Amygdalus persica Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 235000018959 Chrysanthemum indicum Nutrition 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 206010011416 Croup infectious Diseases 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 239000004267 EU approved acidity regulator Substances 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 241001278898 Glycyrrhiza inflata Species 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 235000014435 Mentha Nutrition 0.000 description 1
- 241001072983 Mentha Species 0.000 description 1
- 235000001878 Mentha haplocalyx Nutrition 0.000 description 1
- 244000280293 Mentha haplocalyx Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 241000544428 Phyllostachys glauca Species 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 235000015533 Prunus davidiana Nutrition 0.000 description 1
- 240000002381 Prunus davidiana Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241001165494 Rhodiola Species 0.000 description 1
- 241000997135 Rhodiola crenulata Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 239000001744 Sodium fumarate Substances 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000021240 acute bronchiolitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000008395 clarifying agent Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 201000010549 croup Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- MSJMDZAOKORVFC-SEPHDYHBSA-L disodium fumarate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C\C([O-])=O MSJMDZAOKORVFC-SEPHDYHBSA-L 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000006049 herbal material Substances 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000007603 infrared drying Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 238000005360 mashing Methods 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 229940037525 nasal preparations Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 235000019294 sodium fumarate Nutrition 0.000 description 1
- 229940005573 sodium fumarate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
- A23L2/395—Dry compositions in a particular shape or form
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an antiviral Guanxin No. 1 traditional Chinese medicine composition as well as a preparation method and application thereof, wherein the composition is prepared from the following traditional Chinese medicine raw materials in parts by weight: 15-35 parts of artemisia annua, 10-25 parts of wild chrysanthemum flower, 10-30 parts of peach kernel, 5-15 parts of lophatherum gracile, 10-20 parts of mint, 5-15 parts of liquorice and 5-15 parts of ginseng. The composition has the advantages of homology of medicine and food of raw materials, safety, mildness, easy obtainment of raw materials and lower cost, has better antivirus (particularly coronavirus such as SARS-CoV and SARS-CoV-2) activity, and particularly has better auxiliary effect on the prevention and treatment of respiratory tract infection diseases (such as SARS and COVID-19).
Description
Technical Field
The invention relates to the technical field of medicines, in particular to an antiviral (especially coronavirus resistant, such as SARS-CoV and SARS-CoV-2) composition, a preparation method and application thereof.
Background
Many important infectious diseases in humans are caused by viruses. These diseases include rabies, smallpox, polio, hepatitis, pneumonia, yellow fever, immunodeficiency and various encephalitis diseases, many of which are highly contagious and produce acute discomfort and are often fatal, others such as rubella and cytomegalovirus cause congenital malformations. Coronaviruses are a large family of viruses known to infect the upper respiratory and gastrointestinal tracts of mammals and birds, which can cause colds and more Severe diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS).
On 10.2.2020, the coronavirus research group (CSG) of the International Committee for viral Classification published the latest papers on the platform of preprinting of Life science treatises on the naming of novel coronaviruses, formally "SARS-CoV-2" which is renamed from "2019-nCov". In addition, the world health organization formally named the Disease caused by this Virus as COVID-19(Corona Virus Disease 2019).
The clinical manifestations of covi-19 are mainly fever, cough, shortness of breath, muscle aches, confusion, headache, sore throat, runny nose, chest pain, diarrhea, nausea, vomiting, etc., in more severe cases, the infection may lead to pneumonia, acute respiratory distress syndrome, multiple organ failure, which may aggravate in a short time, or even die. At present, medicaments and methods for effectively treating COVID-19, health-care foods for adjuvant treatment and the like are urgently needed.
Disclosure of Invention
In order to overcome the steps of the prior art, the invention provides an antiviral composition (Guanxin No. 1) and a preparation method and application thereof.
Specifically, the composition is prepared from the following Chinese medicinal raw materials in parts by weight: 15-35 parts of artemisia annua, 10-25 parts of wild chrysanthemum flower, 10-30 parts of peach kernel, 5-15 parts of lophatherum gracile, 10-20 parts of mint, 5-15 parts of liquorice and 5-15 parts of ginseng.
Specifically, in the above Chinese medicinal material raw materials, the weight parts of the artemisia annua can be 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 or 35.
Specifically, in the above traditional Chinese medicine raw materials, the parts by weight of the peach kernel can be 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 parts.
Specifically, in the above traditional Chinese medicine raw materials, the weight portion of the lophatherum gracile may be 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15.
Specifically, in the above traditional Chinese medicine raw materials, the weight portion of the mint can be 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.
Specifically, in the above traditional Chinese medicine raw materials, the weight portion of licorice may be 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15.
Specifically, in the above traditional Chinese medicine raw materials, the weight portion of ginseng can be 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15.
In one embodiment of the present invention, the Chinese herbal medicine material further comprises salvia miltiorrhiza.
Specifically, in the above traditional Chinese medicine raw materials, the weight portion of the salvia miltiorrhiza can be 5-15 (specifically, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15).
In one embodiment of the present invention, the Chinese herbal material further comprises rhodiola rosea.
Specifically, in the above traditional Chinese medicine raw materials, the weight portion of the rhodiola rosea can be 10-20 (specifically, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20).
In one embodiment of the present invention, the composition is prepared from the following Chinese medicinal materials in parts by weight: 15-35 parts of artemisia annua, 10-25 parts of wild chrysanthemum flower, 10-30 parts of peach kernel, 5-15 parts of lophatherum gracile, 10-20 parts of mint, 5-15 parts of liquorice, 5-15 parts of ginseng, 5-15 parts of salvia miltiorrhiza and 10-20 parts of rhodiola rosea.
In one embodiment of the invention, the traditional Chinese medicine raw materials comprise the following components in parts by weight: 15-35 parts of artemisia annua, 10-25 parts of wild chrysanthemum flower, 10-30 parts of peach kernel, 5-15 parts of lophatherum gracile, 10-20 parts of mint, 5-15 parts of liquorice, 5-15 parts of ginseng, 5-15 parts of salvia miltiorrhiza and 10-20 parts of rhodiola rosea.
In one embodiment of the present invention, the composition is prepared from the following Chinese medicinal materials: 1500g of artemisia annua, 1500g of wild chrysanthemum flower, 1000g of peach kernel, 500g of lophatherum gracile, 1000g of mint, 500g of liquorice, 500g of ginseng, 100g of rhodiola rosea and 500g of salvia miltiorrhiza.
In one embodiment of the present invention, the composition is prepared from the following Chinese medicinal materials: 3500g of artemisia annua, 2500g of wild chrysanthemum, 3000g of peach kernel, 1500g of lophatherum gracile, 2000g of mint, 1500g of liquorice and 1500g of ginseng.
In one embodiment of the present invention, the composition is prepared from the following Chinese medicinal materials: 3000g of artemisia annua, 1500g of wild chrysanthemum, 3500g of peach kernel, 1500g of lophatherum gracile, 1500g of mint, 500g of liquorice and 500g of ginseng.
In one embodiment of the present invention, the above composition is a pharmaceutical composition.
Specifically, the pharmaceutical composition further comprises pharmaceutically acceptable auxiliary materials.
Specifically, the pharmaceutically acceptable excipients may include sweetening agents (specifically, sucrose, xylitol, fructo-oligosaccharide, sodium cyclamate, stevioside, aspartame, etc.), flavoring agents (such as flavors, essences, etc.), mucilage agents (specifically, sodium alginate, acacia, gelatin, methylcellulose, sodium carboxymethylcellulose, etc.), clarifying agents (specifically, chitosan, gelatin, etc.), preservatives (specifically, benzoic acid and its salts, sorbic acid and its salts, parabens series, etc.), disintegrating agents (specifically, low-substituted hydroxypropylcellulose, crospovidone, sodium starch glycolate, croscarmellose sodium, starch, etc.), binders (specifically, hydroxypropylcellulose, hypromellose, povidone, copovidone, pregelatinized starch, etc.), lubricants (specifically, stearic acid, magnesium stearate, sodium fumarate, etc.), and the like, One or more of a wetting agent (specifically, polyoxyethylene sorbitan fatty acid ester, poloxamer, polyoxyethylene castor oil derivative, etc.), a suspending agent (specifically, hypromellose, hydroxypropyl cellulose, povidone, copovidone, sodium carboxymethyl cellulose, methyl cellulose, etc.), a stabilizer (specifically, citric acid, fumaric acid, succinic acid, etc.), a filler (specifically, starch, sucrose, lactose, microcrystalline cellulose, etc.), a binder (specifically, cellulose derivative, alginate, gelatin, polyvinylpyrrolidone, etc.), and the like.
Specifically, the above-mentioned pharmaceutical composition may be in any dosage form or administration form, particularly oral dosage form, and those skilled in the art may select it as the case may be, including, but not limited to, tablets (including sugar-coated tablets, film-coated tablets, sublingual tablets, orally disintegrating tablets, buccal tablets, etc.), pills, powders, granules, capsules (including soft capsules, microcapsules), troches, syrups, solutions, emulsions, suspensions, controlled release preparations (e.g., immediate release preparations, sustained release microcapsules), aerosols, films (e.g., orally disintegrating films, oral mucosa-adhering films), injections (e.g., subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections), intravenous drip injections, transdermal absorption preparations, ointments, lotions, adhesive preparations, suppositories (e.g., rectal suppositories, oral administration forms, etc.), oral preparations, and the like, Pessaries), pellets, nasal preparations, pulmonary preparations (inhalants), eye drops, and the like, oral or parenteral preparations (e.g., intravenous, intramuscular, subcutaneous, intraorgan, intranasal, intradermal, instillation, intracerebral, intrarectal, and the like administration forms, administration to the vicinity of a lesion and administration directly to the lesion).
In one embodiment of the present invention, the pharmaceutical composition is a powder.
Specifically, the preparation method of the powder comprises the following steps:
(1) pulverizing herba Artemisiae Annuae and herba Menthae, adding extraction solvent 1, leaching, and separating extraction solvent 1 to obtain raw material powder 1;
extracting other Chinese medicinal materials with extraction solvent 2, separating liquid from solid, and drying the obtained liquid to obtain raw material powder 2;
(2) mixing the raw material powder 1 and the raw material 2 with proper pharmaceutically acceptable auxiliary materials.
In one embodiment of the present invention, in the step (1), the artemisia annua and the mint are pulverized to 80 meshes.
Specifically, the leaching in the step (1) above independently employs: one or more of decocting, percolating, steam distilling, refluxing, soaking, supercritical fluid extracting, and ultrasonic extracting.
In one embodiment of the invention, the artemisia annua and the mint are extracted by an immersion method.
Specifically, in the step (1), the extraction solvent 1 is 80-99% (specifically, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) ethanol; in one embodiment of the invention, the extraction solvent 1 is 95% ethanol.
Specifically, in the step (1), the extraction temperature of artemisia annua and mint is 20-30 ℃ (specifically, 20, 22, 24, 25, 26, 28, 30 ℃); in one embodiment of the invention, the leaching temperature is room temperature.
Specifically, in the step (1), the leaching time of the artemisia annua and the mint is 12-48 hours (specifically, 12, 18, 24, 30, 36, 42 and 48 hours); in one embodiment of the invention, the leaching time is 24 hours.
Specifically, in the step (1), the leaching process of the artemisia annua and the mint further comprises stirring operation.
Specifically, in the above step (1), the separation of the extraction solvent 1 is performed under vacuum.
In one embodiment of the invention, the other Chinese medicinal materials are extracted by decoction.
Specifically, in the step (1), the extraction solvent 2 is water.
Specifically, in the step (1), the leaching times of other traditional Chinese medicine raw materials are 1 or more, for example, 2 times.
Specifically, in the step (1), in the single leaching of other Chinese medicinal materials, the mass-to-volume ratio of the other Chinese medicinal materials to the extraction solvent 2 is 1: 1-10 (specifically, 1: 1, 1: 2, 1: 3, 1: 4, 1: 5, 1: 6, 1: 7, 1: 8, 1: 9, 1: 10); in one embodiment of the invention, the extraction times of other traditional Chinese medicine raw materials are 2 times, the mass volume ratio of the other traditional Chinese medicine raw materials to the extraction solvent 2 in the first extraction is 1: 7, and the mass volume ratio of the other traditional Chinese medicine raw materials to the extraction solvent 2 in the second extraction is 1: 6.
Specifically, in the step (1), in the single leaching of other Chinese herbal medicine raw materials, the leaching time is 0.5 to 6 hours (specifically, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6 hours); in one embodiment of the invention, the leaching time is 1.5 hours.
Specifically, in the step (1), the liquid-solid separation may be performed by one or a combination of filtration, centrifugation, sedimentation, and the like.
Specifically, in the step (1), the drying may be one or a combination of more of normal pressure drying, reduced pressure drying, boiling drying, spray drying, freeze drying, infrared drying, microwave drying, and the like; in one embodiment of the present invention, the drying in step (1) is spray drying.
Specifically, the preparation method of the powder can also comprise a sterilization step.
Specifically, the preparation method of the powder can also comprise the step of subpackaging.
In one embodiment of the present invention, the pharmaceutical composition is a tablet.
Specifically, the preparation method of the tablet may include a step of tableting the above powder.
Specifically, the preparation method of the tablet can further comprise the steps of the preparation method of the powder.
Specifically, the preparation method of the tablet can further comprise a sterilization step.
Specifically, the preparation method of the tablet can further comprise the step of subpackaging.
In one embodiment of the present invention, the pharmaceutical composition is a solution, such as decoction or oral liquid.
Specifically, the preparation method of the solution comprises the following steps:
(1) squeezing herba Artemisiae Annuae and herba Menthae to obtain liquid 1;
extracting other Chinese medicinal materials with extraction solvent 3, and separating liquid from solid to obtain liquid 2;
(2) liquid 1 and liquid 2 are mixed.
Specifically, the rosa roxburghii tratt can be added in the step (1), preferably, the raw materials of the composition also comprise 5-30 parts by weight of rosa roxburghii tratt, and more preferably, the raw materials comprise 5, 10, 15, 20, 25 and 30 parts by weight of rosa roxburghii tratt.
Specifically, the leaching in the step (1) adopts: one or more of decocting, percolating, steam distilling, refluxing, soaking, supercritical fluid extracting, and ultrasonic extracting.
In one embodiment of the present invention, the leaching in the step (1) is performed by a decoction method.
Specifically, in the step (1), the extraction solvent 3 is water.
Specifically, in the step (1) above, the number of times of leaching is 1 or more, for example, 2 times.
Specifically, in the step (1), in the single leaching of other Chinese medicinal materials, the mass-to-volume ratio of the other Chinese medicinal materials to the extraction solvent 3 is 1: 1-10 (specifically, 1: 1, 1: 2, 1: 3, 1: 4, 1: 5, 1: 6, 1: 7, 1: 8, 1: 9, 1: 10); in one embodiment of the invention, the extraction times of other traditional Chinese medicine raw materials are 2 times, the mass volume ratio of the other traditional Chinese medicine raw materials to the extraction solvent 2 in the first extraction is 1: 7, and the mass volume ratio of the other traditional Chinese medicine raw materials to the extraction solvent 2 in the second extraction is 1: 6.
Specifically, in the step (1), in the single leaching of other Chinese herbal medicine raw materials, the leaching time is 0.5 to 6 hours (specifically, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6 hours); in one embodiment of the invention, the leaching time is 1.5 hours.
Specifically, in the step (1), the liquid-solid separation may be performed by one or a combination of filtration, centrifugation, sedimentation, and the like.
Specifically, the preparation method of the solution can also comprise the step of adding appropriate pharmaceutically acceptable auxiliary materials.
Specifically, the preparation method of the solution can also comprise a sterilization step.
Specifically, the preparation method of the solution can also comprise a step of subpackaging.
Other dosage forms of the above pharmaceutical composition can be prepared according to conventional production methods in the pharmaceutical field.
In one embodiment of the present invention, the above composition is a functional food composition.
Specifically, the functional food composition further comprises food auxiliary materials.
Specifically, the food auxiliary materials may include one or more of excipients, fillers, shaping agents, sweeteners, colorants, coating agents, acidity regulators, and the like.
Specifically, the functional food composition may be in any form, such as tablets, pills, capsules (e.g., soft capsules, microcapsules), candies (e.g., tabletted candies, gel candies, gum-based candies, etc.), solid beverages (e.g., powders, granules, etc.), liquid beverages, etc.
The above various forms of the functional food composition can be prepared according to conventional production methods in the field of functional foods.
In one specific embodiment of the invention, the composition is powder and is prepared from the following Chinese medicinal raw materials in parts by weight: 1500g of artemisia annua, 1500g of wild chrysanthemum, 1000g of peach kernel, 500g of lophatherum gracile, 1000g of mint, 500g of liquorice, 500g of ginseng, 100g of rhodiola rosea and 500g of salvia miltiorrhiza, wherein the preparation method comprises the following steps: (1) weighing the medicinal materials; (2) crushing herba Artemisiae Annuae and herba Menthae into 80 mesh, adding 95% alcohol, soaking for 24 hr, stirring, filtering, and vacuum recovering alcohol to obtain first powder; (3) adding 7 times (w/w) of water into other Chinese medicinal materials, decocting for 1.5 hours, adding 6 times (w/w) of water again, decocting for 1.5 hours, filtering with a 300-mesh sieve, and spray drying to obtain No. two raw material powder; (4) mixing the first raw material powder and the second raw material powder, adding fructo-oligosaccharide, and filling.
In one embodiment of the invention, the composition is a tablet and is prepared from the following Chinese medicinal raw materials in parts by weight: 3500g of artemisia annua, 2500g of wild chrysanthemum, 3000g of peach kernel, 1500g of lophatherum gracile, 2000g of mint, 1500g of liquorice and 1500g of ginseng, and the preparation method comprises the following steps: (1) weighing the medicinal materials; (2) crushing the artemisia annua and the mint to 80 meshes, adding 95% alcohol, soaking for 24 hours, stirring in the middle, filtering, and recovering the alcohol in vacuum to form a first raw material powder; (3) adding 7 times (w/w) of water into other Chinese medicinal materials, decocting for 1.5 hours, adding 6 times (w/w) of water again, decocting for 1.5 hours, filtering with a 300-mesh sieve, and spray drying to obtain No. two raw material powder; (4) mixing the first powder and the second powder, adding fructo-oligosaccharide and xylitol, spraying plant essential oil, and tabletting.
In one specific embodiment of the invention, the composition is an oral liquid and is prepared from the following Chinese medicinal raw materials in parts by weight: 3000g of artemisia annua, 1500g of wild chrysanthemum, 3500g of peach kernel, 1500g of lophatherum gracile, 1500g of mint, 500g of liquorice and 500g of ginseng, and the preparation method comprises the following steps: (1) weighing the medicinal materials; (2) adding 7 times (w/w) of water into other Chinese medicinal materials for the first time and 6 times (w/w) of water into the other Chinese medicinal materials for the second time, decocting for 1.5 hours respectively, filtering by a 300-mesh sieve, standing for 24 hours (a refrigerator), and taking supernatant which is No. 2 liquid; (4) mixing the first liquid and the second liquid, adding purified water, and cooling.
The invention also provides application of the composition in preparing a medicament for preventing and/or treating virus infection.
The invention also provides application of the composition in preparing functional food of a medicament for preventing virus infection or for adjuvant therapy of virus infection.
Specifically, the virus may be selected from the group consisting of adenoviridae, herpesviridae (e.g., EBV), papovaviridae, picornaviridae, poxviridae (e.g., smallpox virus), hepadnaviridae (e.g., hepatitis B virus), coronaviridae (e.g., HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV, MERS-CoV, SARS-CoV-2, etc.), poonaviridae, Filoviridae (e.g., Ebola virus), Orthomyxoviridae (e.g., influenza A virus, influenza B virus), Paramyxoviridae (e.g., human parainfluenza virus type 1 (HPV), HPV type 2, HPV type 3, HPV type 4, Sendai virus, mumps virus, measles virus, respiratory syncytial virus, Newcastle disease virus, etc.), Retroviridae (e.g., HIV), reoviridae, Rhabdoviridae (e.g., rabies virus), and the like.
In one embodiment of the present invention, the virus is selected from: orthomyxovirus, paramyxovirus, adenovirus, coronavirus.
In one embodiment of the present invention, the virus is a coronavirus, specifically HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV, MERS-CoV, SARS-CoV-2, and the like.
The present invention also provides a method for preventing and/or treating a disease or condition caused by or associated with a viral infection, or aiding such prevention and/or treatment, comprising the step of administering to a subject the above-described composition of the present invention.
Specifically, the disease or condition may include one or more of acute bronchitis, chronic bronchitis, rhinitis, sinusitis, croup, acute bronchiolitis, pharyngitis, tonsillitis, laryngitis, tracheitis, asthma, pneumonia, etc.
In one embodiment of the present invention, the disease is COVID-19.
In particular, the subject is a mammal, such as a primate, in particular a human.
In one embodiment of the present invention, the subject is a suspected infected person.
In another embodiment of the present invention, the subject is a patient with early or intermediate stage infection.
In another embodiment of the present invention, the subject is a high risk patient, such as a COPD patient, an asthma patient, a patient suffering from allergy, an individual with an impaired immune system, cardiovascular system or pulmonary system, a transplant patient, and the like.
The invention provides a method for resisting virus and providing a more extensive and effective mode besides vaccine, the invention adopts the food-therapy and food-nourishing mode of traditional Chinese medicine to provide an antiviral composition, in particular, the antiviral composition can be used as non-medicine dietary food for supplementing body energy, and auxiliary medicines for treating, preventing and blocking virus (in particular, coronavirus such as SARS-CoV and SARS-CoV-2), effectively improves the symptoms of cough, shortness of breath, hypodynamia, anxiety and the like of respiratory tract infection diseases (such as SARS and COVID-19) caused by virus infection, is helpful for relieving the state of illness, has certain auxiliary effect on the health recovery of patients with confirmed diagnosis, and has psychological comfort effect on the people without confirmed diagnosis.
Detailed Description
Unless defined otherwise, all scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains, for example:
and (3) artemisia annua: whole plant of Artemisia annua Linn of Compositae; the taste is pungent, bitter, cool, nontoxic, bitter and cold; the efficacy is as follows: clearing heat, removing malaria, dispelling pathogenic wind and relieving itching; the processing method comprises the following steps: dried in the sun or cut into segments and dried in the sun.
Wild chrysanthemum flower: capitula of Chrysanthemum indicum L. of Compositae; bitter and pungent taste, slightly cold nature; entering liver and heart meridians; the efficacy is as follows: clearing away heat and toxic material, purging fire and calming the liver; the processing method comprises the following steps: dried in the sun or steamed and then dried in the sun.
Peach kernel: dried mature seeds of Prunus persica (L.) or Prunus davidiana (Carr.) of Rosaceae; bitter and sweet in taste and mild in nature; the heart, liver and large intestine meridians entered; the efficacy is as follows: promoting blood circulation, removing blood stasis, loosening bowel to relieve constipation, relieving cough and asthma; the processing method comprises the following steps: removing impurities and oily seeds, and mashing.
Herba lophatheri: leaves of Phyllostachys glauca McClure of Gramineae; sweet and light taste, cold in nature; entering heart, lung and stomach meridians; the efficacy is as follows: clearing away heat, relieving restlessness, promoting salivation, and promoting urination; collecting and processing: the fresh product is collected at any time and used as medicine.
Mint: dried aerial parts of Mentha haplocalyx Briq. of Mentha of Labiatae; pungent taste and cool nature; entering lung and liver meridians; the efficacy is as follows: disperse wind-heat, clear head and eyes, relieve sore throat, promote eruption, soothe liver and promote qi circulation; the processing method comprises the following steps: removing old stems and impurities, slightly spraying clear water, slightly moistening, cutting into short segments, and drying at low temperature in time.
Licorice root: dried root and rhizome of Glycyrrhiza uralensis Fisch, Glycyrrhiza inflata Bat, or Glycyrrhiza glabra L, of Leguminosae; sweet in taste and neutral in nature; entering heart, lung, spleen and stomach meridians; the efficacy is as follows: invigorating spleen and replenishing qi, clearing away heat and toxic materials, eliminating phlegm and relieving cough, relieving spasm and pain, and harmonizing the above medicines; the processing method comprises the following steps: removing impurities, cleaning, moistening, slicing, and drying.
Ginseng: dried root of Panax ginseng C.A.Mey. of Araliaceae family, sweet, slightly bitter, neutral in nature; the medicine has the effects of invigorating spleen, lung and heart channels: invigorating primordial qi, restoring pulse, relieving depletion, invigorating spleen, benefiting lung, promoting fluid production, and tranquilizing, and the preparation method comprises: moistening, slicing, and drying.
Red sage root: dried root and rhizome of Salvia Miltiorrhiza bge of Labiatae; bitter taste and slightly cold nature; heart and liver meridian entered; the efficacy is as follows: promoting blood circulation, removing blood stasis, dredging channels, relieving pain, clearing heart fire, relieving restlessness, cooling blood, and eliminating carbuncle; the processing method comprises the following steps: removing impurities and residual stem, cleaning, moistening, slicing, and drying.
Rhodiola root: dried roots and rhizomes of Rhodiola crenulata Rhodiola rosea l. of the family sedaceae; sweet and bitter taste, mild in nature; enter lung and heart meridians, and have the following effects: replenishing qi, activating blood circulation, dredging collaterals and relieving asthma; the processing method comprises the following steps: removing root hair and impurities, slicing and drying.
In the present invention, the functional food refers to a food having specific nutritional health-care functions, i.e., a food suitable for specific people to eat, having a function of regulating the body, and not aiming at treatment. Functional foods are sometimes also referred to as nutraceutical foods.
The technical solutions of the present invention will be described clearly and completely with reference to the following embodiments of the present invention, and it should be understood that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1: preparation of powders
The formula comprises the following components:
1500g of artemisia annua, 1500g of wild chrysanthemum flower, 1000g of peach kernel, 500g of lophatherum gracile, 1000g of mint, 500g of liquorice, 500g of ginseng, 100g of rhodiola rosea and 500g of salvia miltiorrhiza.
The preparation process comprises the following steps:
(1) weighing the medicinal materials according to the formula;
(2) crushing herba Artemisiae Annuae and herba Menthae into 80 mesh, adding 95% alcohol, soaking for 24 hr, stirring, filtering, and vacuum recovering alcohol to obtain first powder;
(3) adding 7 times (w/w) of water into other Chinese medicinal materials, decocting for 1.5 hours, adding 6 times (w/w) of water again, decocting for 1.5 hours, filtering with a 300-mesh sieve, and spray drying to obtain No. two raw material powder;
(4) mixing the first raw material powder and the second raw material powder, adding fructo-oligosaccharide, and filling.
Example 2: tablet preparation
The preparation process comprises the following steps:
the formula comprises the following components:
3500g of artemisia annua, 2500g of wild chrysanthemum, 3000g of peach kernel, 1500g of lophatherum gracile, 2000g of mint, 1500g of liquorice and 1500g of ginseng.
The preparation process comprises the following steps:
(1) weighing the medicinal materials according to the formula;
(2) crushing herba Artemisiae Annuae and herba Menthae into 80 mesh, adding 95% alcohol, soaking for 24 hr, stirring, filtering, and vacuum recovering alcohol to obtain first powder;
(3) adding 7 times (w/w) of water into other Chinese medicinal materials, decocting for 1.5 hours, adding 6 times (w/w) of water again, decocting for 1.5 hours, filtering with a 300-mesh sieve, and spray drying to obtain No. two raw material powder;
(4) mixing the first powder and the second powder, adding fructo-oligosaccharide and xylitol, spraying plant essential oil, and tabletting to obtain about 10000 tablets.
Example 3: preparation of oral liquid
The formula comprises the following components:
3000g of artemisia annua, 1500g of wild chrysanthemum, 3500g of peach kernel, 1500g of lophatherum gracile, 1500g of mint, 500g of liquorice and 500g of ginseng.
The preparation process comprises the following steps:
(1) weighing the medicinal materials according to the formula;
(2) taking artemisia annua and mint, adding 2000g of roxburgh rose, squeezing into juice, and preparing into liquid I;
(3) decocting other Chinese medicinal materials with water 7 times (w/w) and water 6 times (w/w) for 1.5 hr respectively, filtering with 300 mesh sieve each time, standing for 24 hr (icehouse), and collecting supernatant as No. 2 liquid;
(4) mixing the first liquid and the second liquid, adding 10 times (w/w) of purified water, and cooling.
Example 4
At present, an urgent and lasting epidemic situation war still develops the research of the solution of countercheck diagnosis and treatment, the effective progress is also made in the aspect of traditional Chinese pharmacology, and the temperate and the recuperation performance of the traditional Chinese medicine properly help the delay of the epidemic situation under the condition that no specific medicine exists.
1. Experimental design and Baseline
Volunteers were selected as medical personnel, patients, and investigation and observation were started in both confirmed and undiagnosed groups of people. Basic information is filled in through a questionnaire, and symptom scores are analyzed to know symptom conditions and health states. The total of 9 patients with confirmed diagnosis and 42 healthy or sub-healthy groups with no confirmed diagnosis was 51 clinical data.
TABLE 1 demographic data
From the baseline in table 1, women were more abundant, accounting for 78%, and the age was generally mid-year (average 42.8 years). 62.7% of medical staff and only 9 confirmed diagnosis staff account for 17.6% of the total investigation. The BMI indicator indicates that 45.1% of people are not between 18-24 and may have health problems.
TABLE 2 diagnosis and President Inquiry
From the clinical stages in Table 2, two severe cases, one medium case and the other common cases, were observed, and the disease history (past history, allergic history, family history) was not significantly different between confirmed and undiagnosed volunteers. At present, because no effective western medicine exists, the taken medicine is biased to the traditional Chinese medicine.
2. Treatment regimens of the invention
The volunteers took the tablets prepared in example 2 and took them 3-5 tablets 3 times a day with 100ml of the oral liquid prepared in example 3. Questionnaires were completed before and after administration.
3. Results and conclusions
TABLE 3 symptomatology
As can be seen from the symptoms in Table 3, the patients with confirmed diagnosis have the symptoms of shortness of breath, weakness, chest distress, dry cough, heaviness of the head and body, and the like, but the other symptoms are general. The conditions of undiagnosed patients are different, and more symptoms are manifested by dry throat and hypodynamia, and the symptoms can have certain guidance on the application of the medicine.
TABLE 4 self-rating Change before and after visit
TABLE 4.1 heating conditions
TABLE 4.2 cough status
TABLE 4.3 chest stuffiness
TABLE 4.4 short breath conditions
TABLE 4.5 fatigue
TABLE 4.6 action cases
TABLE 4.7 self-care situations
TABLE 4.8 daily activities (e.g. work, study, housework, home or leisure activities) situation
TABLE 4.9 pain/discomfort
TABLE 4.10 anxiety (e.g., tension, worry, restlessness, etc.)/depression (e.g., lack of interest, no enjoyment, inability to raise spirit, etc.) cases
As seen from the change before and after the visit of a series of symptoms in the table 4, after the volunteers take the health-care food, the cough, the shortness of breath, the hypodynamia and the anxiety are changed, and a certain curative effect is achieved; fever, movement, self-care and pain have no obvious change; meanwhile, chest distress needs to be considered, so that the possibility of aggravation of the patient is not eliminated.
TABLE 5 Total health score Change before and after visit
Table 5 the change of the total score of health before and after visit shows that the health food of the present invention has certain effect and curative effect on the recovery of the patients with confirmed diagnosis and simultaneously has the effect of psychological comfort to the people without confirmed diagnosis. As a non-medicinal dietary nutrition supplement preparation, the health food has certain psychological comfort and auxiliary curative effects, and can slightly relieve serious illness and danger.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents and the like that are within the spirit and principle of the present invention are intended to be included therein.
Claims (10)
1. The composition is characterized by being prepared from the following Chinese medicinal raw materials in parts by weight: 15-35 parts of artemisia annua, 10-25 parts of wild chrysanthemum flower, 10-30 parts of peach kernel, 5-15 parts of lophatherum gracile, 10-20 parts of mint, 5-15 parts of liquorice and 5-15 parts of ginseng.
2. The composition of claim 1, wherein the composition is prepared from the following Chinese medicinal materials in parts by weight: 20-30 parts of artemisia annua, 15-20 parts of wild chrysanthemum flower, 15-25 parts of peach kernel, 8-12 parts of lophatherum gracile, 12-18 parts of mint, 8-12 parts of liquorice and 8-12 parts of ginseng.
3. The composition of claim 1, wherein the Chinese medicinal material further comprises 5-15 parts of salvia miltiorrhiza, and/or 10-20 parts of rhodiola rosea.
4. The composition of claim 1, wherein the composition is prepared from raw materials comprising: 1500g of artemisia annua, 1500g of wild chrysanthemum, 1000g of peach kernel, 500g of lophatherum gracile, 1000g of mint, 500g of liquorice, 500g of ginseng, 100g of rhodiola rosea and 500g of salvia miltiorrhiza; or the like, or, alternatively,
the composition is prepared from the following Chinese medicinal materials: 3500g of artemisia annua, 2500g of wild chrysanthemum, 3000g of peach kernel, 1500g of lophatherum gracile, 2000g of mint, 1500g of liquorice and 1500g of ginseng; or the like, or, alternatively,
the composition is prepared from the following Chinese medicinal materials: 3000g of artemisia annua, 1500g of wild chrysanthemum, 3500g of peach kernel, 1500g of lophatherum gracile, 1500g of mint, 500g of liquorice and 500g of ginseng.
5. The composition according to any one of claims 1 to 4, wherein the composition is a functional food composition.
6. The composition of claim 5, wherein the functional food composition is a tablet, a pill, a capsule, a candy, a solid beverage, or a liquid beverage.
7. The composition of claim 6, wherein the functional food composition further comprises a food adjuvant;
preferably, the food auxiliary materials comprise one or more of excipient, filling agent, forming agent, sweetener, coloring agent, coating agent and acidity regulator.
8. The composition of claim 6, wherein the candy comprises a tabletted candy, a gel candy, a gum base candy; the solid beverage comprises powder and granules.
9. Use of a composition according to any one of claims 1 to 4 for the preparation of a medicament for the prevention and/or treatment of viral infections, or a functional food for the prevention of viral infections or for the adjunctive treatment of viral infections.
10. The use according to claim 9, wherein the virus is of the family adenoviridae, herpesviridae, papovaviridae, picornaviridae, poxviridae, hepadnaviridae, coronaviridae, potaviridae, filoviridae, orthomyxoviridae, paramyxoviridae, retroviridae, reoviridae or rhabdoviridae;
preferably, the filoviridae family is ebola virus;
preferably, the orthomyxovirus is an influenza a virus or an influenza b virus;
preferably, the paramyxovirus is selected from the group consisting of: one or more of HPV type 1, HPV type 2, HPV type 3, HPV type 4, Sendai virus, mumps virus, measles virus, respiratory syncytial virus, and Newcastle disease virus;
preferably, the virus is selected from: one or more of HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARs-CoV, MERS-CoV, SARS-CoV-2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010090982 | 2020-02-13 | ||
| CN2020100909823 | 2020-02-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111803593A true CN111803593A (en) | 2020-10-23 |
Family
ID=72848008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010482309.4A Pending CN111803593A (en) | 2020-02-13 | 2020-05-29 | Antiviral traditional Chinese medicine composition, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111803593A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102020006998A1 (en) | 2020-11-16 | 2022-05-19 | Hermann-Josef Wilhelm | Method for cultivating a plant with at least one antiviral active ingredient, and use of the plant ingredient itself |
| KR20220083218A (en) * | 2020-12-11 | 2022-06-20 | 숙명여자대학교산학협력단 | Composition for anti-coronavirus containing extract of Prunus genus |
| CN115364136A (en) * | 2022-09-05 | 2022-11-22 | 深圳市药品检验研究院（深圳市医疗器械检测中心） | Application of Crassulaceae plant extract in preparing medicine for resisting novel coronavirus and influenza virus infection |
| KR102524075B1 (en) * | 2022-06-22 | 2023-04-21 | 한국 한의학 연구원 | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1723922A (en) * | 2004-07-22 | 2006-01-25 | 广州中医药大学科技产业园有限公司 | Medicine for treating viral influenza, and its prepn. method |
| CN104042947A (en) * | 2014-06-10 | 2014-09-17 | 周晓明 | Preparation with effect of clearing heat from throat and preparation method thereof |
-
2020
- 2020-05-29 CN CN202010482309.4A patent/CN111803593A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1723922A (en) * | 2004-07-22 | 2006-01-25 | 广州中医药大学科技产业园有限公司 | Medicine for treating viral influenza, and its prepn. method |
| CN104042947A (en) * | 2014-06-10 | 2014-09-17 | 周晓明 | Preparation with effect of clearing heat from throat and preparation method thereof |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102020006998A1 (en) | 2020-11-16 | 2022-05-19 | Hermann-Josef Wilhelm | Method for cultivating a plant with at least one antiviral active ingredient, and use of the plant ingredient itself |
| KR20220083218A (en) * | 2020-12-11 | 2022-06-20 | 숙명여자대학교산학협력단 | Composition for anti-coronavirus containing extract of Prunus genus |
| KR102640518B1 (en) | 2020-12-11 | 2024-02-27 | 숙명여자대학교산학협력단 | Composition for anti-coronavirus containing extract of Prunus genus |
| KR102524075B1 (en) * | 2022-06-22 | 2023-04-21 | 한국 한의학 연구원 | Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component |
| CN115364136A (en) * | 2022-09-05 | 2022-11-22 | 深圳市药品检验研究院（深圳市医疗器械检测中心） | Application of Crassulaceae plant extract in preparing medicine for resisting novel coronavirus and influenza virus infection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111803593A (en) | Antiviral traditional Chinese medicine composition, preparation method and application thereof | |
| WO2021169026A1 (en) | Traditional chinese medicine composition for preventing epidemics, and preparation method therefor and use thereof | |
| CN102872261B (en) | The application of Physalis pubescens L. in the medicine of preparation treatment acute cholecystitis | |
| WO2021179505A1 (en) | Forsythia suspensa and astragalus membranaceus compound preparation, preparation method therefor and application thereof | |
| CN108403882B (en) | Salvia miltiorrhiza composition for treating coronary heart disease and preparation method thereof | |
| CN110237174A (en) | A kind of eliminating dampness Chinese medicine composition and preparation method thereof for treating cold cough | |
| CN110193061B (en) | Preparation and application of traditional Chinese medicine granules for treating or preventing children influenza virus infection | |
| CN102139051B (en) | Application of soft capsule capable of clearing heat and eliminating toxin in preparation of medicament for treating viral pneumonia | |
| CN100509009C (en) | Chinese medicinal preparation for treating heart cerebrovascular disease and ischemic apoplexia and making method thereof | |
| CN106539908A (en) | A kind of Chinese medicine composition for treating allergic rhinitises and skin allergy | |
| CN102178792B (en) | Shiqi exogenous Chinese medicinal buccal tablets | |
| CN1326552C (en) | Medicine for treating viral influenza, and its prepn. method | |
| CN106075229A (en) | A kind of Chinese medicinal composition preparation treating anemopyretic cold | |
| CN103961441A (en) | Traditional Chinese medicine compound preparation, preparation method and medicine box thereof | |
| CN103301244B (en) | Traditional Chinese medicinal preparation for treating infantile pneumonia and preparation method of traditional Chinese medicinal preparation | |
| CN102349979A (en) | Oral traditional Chinese medicine composition for treating bitter taste in mouth | |
| CN111529575A (en) | A pharmaceutical composition for treating gout and/or hyperuricemia, and its preparation method | |
| CN102357207B (en) | Traditional Chinese medicine composition for curing hypertension | |
| CN104225073A (en) | Preparation method and application of cortex lycii radicis total flavone | |
| CN102772665B (en) | Traditional Chinese medicine preparation for treating yin deficiency and internal heat type vital myocarditis and preparation method thereof | |
| CN106138259B (en) | Traditional Chinese medicine composition for treating wind-heat type common cold and preparation method thereof | |
| CN102973856B (en) | Anti-cold pharmaceutical composition and preparation method thereof | |
| CN113521206B (en) | Traditional Chinese medicine composition containing burdock | |
| CN102247470B (en) | A kind of Chinese medicine composition preventing and treating infant upper respiratory tract infection | |
| CN107596107B (en) | Heat-clearing, sore-throat-relieving and anti-allergic traditional Chinese medicine preparation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |